

December 30, 2021

Public Notice: GenBody COVID-19 Ag Kits Efficacy in New SARS-CoV-2 Variants

GenBody has been closely monitoring all variants of concern (VOC) and their potential impact upon the performance of the GenBody COVID-19 Ag test. On December 3, 2021, sequence analysis testing was performed which indicated that the Omicron variant (B.1.1.529) was not likely to have a clinically significant impact on test performance.

Additional follow-up testing with recombinant protein confirmed the GenBody COVID-19 Ag can detect the Omicron variant. Moreover, continued confirmatory testing using live virus samples is ongoing to ensure that the GenBody COVID-19 Ag test remains an effective tool in the fight against the COVID-19 pandemic. As each new variant emerges, GenBody is committed to a thorough and ongoing evaluation of our product efficacy.

Sincerely,

J. S. Kim

Jin Soo Kim
Chief Executive Officer
GenBody Inc.